Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic nonspecific intestinal inflammatory disease with a chronic course of recurrent relapse and remission.[1, 2, 3] Although biological therapies, such as antitumor necrosis factor‐α (TNF‐α) therapy, have been widely used and have shown satisfactory efficacy in clinical settings, a significant number of patients do not benefit from these therapies or fail to maintain long‐term mucosal healing and clinical remission. Here, TNF is linked to inflammatory bowel disease.